Description: Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Home Page: www.replimune.com
500 Unicorn Park Drive
Woburn,
MA
01801
United States
Phone:
781 222 9600
Officers
| Name | Title |
|---|---|
| Mr. Philip Astley-Sparke F.S.A. | Executive Chairman |
| Ms. Emily Luisa Hill | Chief Financial Officer |
| Dr. Konstantinos Xynos M.B.A., M.D., Ph.D. | Chief Medical Officer |
| Dr. Sushil Patel Ph.D. | CEO & Director |
| Dr. Robert Coffin Ph.D. | Founder, Chief Scientist & Director |
| Mr. Andrew Schwendenman | Chief Accounting Officer & Treasurer |
| Mr. Christopher Sarchi | Chief Commercial Officer |
| Mr. Paul Bullock | Chief Manufacturing Officer & Framingham Site Head |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.6053 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 331 |